1. Eli Lilly reduces cash prices for Zepbound, aiding U.S. patients' costs. 2. Stock dipped 0.8% despite increased demand for the drug. 3. Price cut signals strong demand yet might impact revenue. 4. Consumer savings could enhance brand loyalty for Eli Lilly products.